EQS-News: Asklepios Kliniken
/ Key word(s): Annual Report
Asklepios Group: Solid performance in 2022 Hamburg, 28 April 2023. 2022 was a challenging financial year for Asklepios Kliniken GmbH & Co. KGaA that was dominated by global political and economic developments. The Asklepios Group’s healthcare facilities treated around 3.6 million patients in the 2022 financial year, a slight increase on the previous year (2021: 3.5 million). The Asklepios Group generated revenue of EUR 5.3 billion in the 2022 financial year (previous year: EUR 5.1 billion). Consolidated net operating income (EAT) amounted to EUR 131.9 million (2021: 106.3 million). Capital expenditure totalled EUR 314.0 million in the 2022 financial year (2021: EUR 332.6 million), while the internal financing ratio amounted to 69.5% (2021: 72.8%). The Asklepios Group enjoyed a stable financial position at the end of the 2022 financial year. The Group’s net debt amounted to EUR 1,376.8 million as at 31 December 2022 (31 December 2021: EUR 1,364.8 million), while cash and cash equivalents amounted to EUR 634.6 million (31 December 2021: EUR 647.2 million). The ratio of net debt to EBITDA for the past 12 months was 3.5x (31 December 2021: 3.6x). Asklepios will respond flexibly to the expected regulatory requirements in order to mitigate the potential effects on its business activity. Thanks to strategic investments in digitalisation and the shift towards outpatient care, as well as internally financed capital expenditure on its healthcare facilities amounting to EUR 218.3 million, Asklepios has created a sound basis for weathering the challenges well in economic terms. Overall, Asklepios anticipates stable revenue growth and largely positive economic development in 2023.
IR contact PR contact
Visit Asklepios online, on Facebook or on YouTube: gesundleben.asklepios.com
28.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
1619907 28.04.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.